This Neil Woodford favourite looks attractive after Q4 update

This small-cap with Neil Woodford support looks quite attractive after today’s update.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in ReNeuron (LSE: RENE) jumped by as much as 14% in early deals this morning after the company published two exciting product updates.

Firstly, the company announced this morning that it has successfully developed a cryopreserved formulation of its human retinal progenitor cell therapeutic candidate, a huge milestone quickly as it will enable the cells to be frozen for shipping and storage and easily thawed at the point of clinical use. This development should significantly increase the lifespan of cell therapy treatments, which target degenerative diseases of the retina.

The new formulation has also allowed the firm to expand its clinical programmes in ophthalmology. Expansion of the company’s clinical trials to more patients is planned, and management is looking to test its existing treatment on cone-rod dystrophy patients in an attempt to diversify the business’s markets.

Alongside the above news ReNeuron, which is a favourite of star hedge fund manager Neil Woodford, also announced today that it is planning to start a randomised, placebo-controlled, Phase III clinical trial in the US and Europe in patients who are living with disability post-stroke of its CTX cell therapy candidate for stroke disability. ReNeuron received positive data from its Phase II clinical trial for this product at the end of last year and the commencement of the Phase III testing is a another step closer to commercialisation.

Unfortunately, thanks to the success of these two products, ReNeuron’s management has decided to put the programme for critical limb ischaemia on hold for the time being and concentrate on the “significant opportunity presented by our stroke disability programme and our expanded retinal disease programmes.

Time to buy?

There’s no denying that ReNeuron has made considerable progress with the development of its early-stage treatments over the past two years. Still, as with all early-stage pharmaceutical companies, ReNeuron is a risky investment and the market’s treatment of shares in the company over the past 12 months shows just how cautious investors are about the firm’s prospects. Indeed, since the end of April 2016 shares in ReNeuron have declined by 27% and since April 2015 the shares are down 44%.

However, there may not be much more downside for the shares as at the time of writing the company’s market capitalisation is £70 million, which is only just above the £60 million of cash ReNeuron reported at the end of September 2016. 

Based on historical figures, the firm is burning around £7m in cash every six months, so it’s reasonable to assume that at the end of March ReNeuron had a cash balance of £53m, around 1.7p per share. And even though it can take several years for treatments to move through the testing process, it looks as if ReNeuron has enough cash on hand to remain solvent until its products hit the market.

The bottom line

So overall, if you’re looking for a blue sky growth company that is supported by one of the UK’s most prolific investors and has a cash rich balance sheet, ReNeuron could be a company worthy of further research.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »